Background: In response to the challenges of assessing fetal growth in obese women, guidelines recommend routine third trimester ultrasound scans.
Aim: The aim of this study was to assess the diagnostic performance of this routine scan in obese women (body mass index (BMI) ≥ 35 kg/m ).
Methods: A retrospective cohort study of 1008 pregnancies with maternal BMI ≥ 35 kg/m born after 37 weeks gestation at a Victorian hospital from 2015 to 2017. Multiple pregnancies and those affected by diabetes were excluded. Growth ultrasounds were performed between 34 + 0 and 36 + 6 weeks gestation. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the detection of large for gestational age (LGA > 90%) and small for gestational age (SGA < 10%) were calculated using ultrasound estimated fetal weight (EFW) or abdominal circumference (AC) and compared with gestational age and gender-based birthweight percentiles.
Results: Using EFW, sensitivity for detecting SGA at birth was 8.1% (six of 74) with a PPV of 100%. Sensitivity for detecting LGA at birth was 61.0% (119 of 195), PPV 54.8%. Sensitivity, specificity, PPV and NPV percentages were all lower using AC. Only 40% of actual birthweight percentiles (405/1008) were within ±10 percentiles of their growth ultrasound EFW percentile.
Conclusion: The performance of a routine third trimester ultrasound in women with BMI ≥ 35 kg/m suggests limited utility in helping identify aberrant fetal growth. This has important implications for the management of obese pregnant women.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ajo.13256 | DOI Listing |
Ann Thorac Surg Short Rep
March 2023
Department of Pediatric Surgery, Children's Hospital of Eastern Switzerland, St Gallen, Switzerland.
Background: The minimally invasive repair of pectus excavatum (PE), introduced by Nuss in 1998, represents the worldwide "gold standard" procedure for surgical repair. Modifications over years included routine use of unilateral or bilateral thoracoscopy as well as sternal elevation before starting the substernal dissection. In patients with a severe PE deformity, such as Grand Canyon type, use of a second bar or, in selected patients, even a third or fourth bar has to be considered.
View Article and Find Full Text PDFAnn Thorac Surg Short Rep
September 2024
Division of Thoracic Surgery, Department of Surgery, Hackensack Meridian Health Network, Hackensack, New Jersey.
Background: In 2022, the American Association for Thoracic Surgery (AATS) and the European Society of Thoracic Surgeons (ESTS) published joint guidelines regarding the timing, duration, and choice of agent for perioperative venous thromboembolism prophylaxis for thoracic cancer patients. Now, 1 year after their release, we looked to assess practices and general adherence to these recommendations.
Methods: We conducted a survey among board-certified/board-eligible thoracic surgeons in the United States, between July and October 2023.
Heart
January 2025
Heart Failure Center, Department of Cardiology, China-Japan Friendship Hospital, Beijing, China
Background: Heart failure (HF) guidelines recommend routine testing for iron deficiency (ID) and, for those with ID, intravenous iron if the left ventricular ejection fraction is <50%. Guideline adherence to these recommendations by cardiologists in China is unknown.
Methods And Results: An independent academic web-based survey was designed and distributed via social networks to cardiologists across China.
Phys Med
January 2025
Division of Radiology, "Istituto Nazionale Tumori IRCCS Fondazione Pascale, IRCCS di Napoli, 80131 Naples, Italy.
Purpose: To study the application of radiomics in cancer imaging with a focus on lung cancer, renal cell carcinoma, gastrointestinal cancer, and head and neck cancer.
Methods: Different electronic databases were considered. Articles published in the last five years were analyzed (January 2019 and December 2023).
JAMA Ophthalmol
January 2025
Xiamen Eye Center of Xiamen University, Xiamen, Fujian, China.
Importance: Bietti crystalline dystrophy (BCD) is a severe genetic retinopathy caused by variants in the CYP4V2 gene. Currently, there is no approved treatment for BCD.
Objective: To evaluate safety and vision outcomes following gene therapy with adeno-associated virus (AAV) encoding CYP4V2 (rAAV-hCYP4V2, NGGT001 [Next Generation Gene Therapeutics]).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!